SEC Info - ARCA biopharma, Inc. - ‘8-K’ for 8/2/22

SEC Info℠

Home

Help

Please Sign In

ARCA biopharma, Inc. – ‘8-K’ for 8/2/22

On: Tuesday, 8/2/22, at 4:31pm ET · For: 8/2/22 · Accession #: 1564590-22-27494 · File #: 0-22873

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/02/22  ARCA biopharma, Inc.              8-K:2,9     8/02/22   11:565K                                   ActiveDisclosure/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     37K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    127K 
 6: R1          Document and Entity Information                     HTML     47K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- abio-8k_20220802_htm                XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- abio-20220802_lab                     XML     58K 
 5: EX-101.PRE  XBRL Presentations -- abio-20220802_pre              XML     35K 
 3: EX-101.SCH  XBRL Schema -- abio-20220802                         XSD     18K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
11: ZIP         XBRL Zipped Folder -- 0001564590-22-027494-xbrl      Zip     21K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i 0000907654 0000907654 2022-08-02 2022-08-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i August 2, 2022

i ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

i Delaware	i 000-22873	i 36-3855489
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

i 10170 Church Ranch Way, i Suite 100, i Westminster, i CO		i 80021
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: ( i 720) i 940-2200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common	i ABIO	i Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 2 — Financial Information

Item 2.02.

Results of Operations and Financial Condition.

On August 2, 2022, ARCA biopharma, Inc., or ARCA, issued a press release reporting financial results for the quarter ended June 30, 2022.

The press release is attached hereto as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description

99.1		Press Release titled “ARCA biopharma Announces Second Quarter 2022 Financial Results” dated August 2, 2022.
104		Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: August 2, 2022

	ARCA biopharma, Inc.
	(Registrant)

	By:	/s/ *C. Jeffrey Dekker*
		Name:	C. Jeffrey Dekker
		Title:	Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	8/2/22	10-Q
	6/30/22	10-Q
		List all Filings

↑Top

Filing Submission 0001564590-22-027494 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)